deltatrials
Active Not Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT03960177

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

An Open-Label, Multi-Institutional Pilot Study to Assess the Use of Glucarpidase in Adult Patients With Osteosarcoma Receiving High-Dose Methotrexate

Sponsor: BTG International Inc.

Conditions Osteosarcoma
Interventions Glucarpidase Quality-of-Life Assessment
Updated 18 times since 2019 Last updated: Jan 5, 2026 Started: Mar 27, 2019 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Osteosarcoma and is currently ongoing. BTG International Inc. leads this study, which shows 18 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jul 2022 · 7 months · monthly snapshot~Jul 2022 – ~Jan 2023 · 6 months · monthly snapshot~Jan 2023 – ~Jun 2023 · 5 months · monthly snapshot~Jun 2023 – ~Dec 2023 · 6 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Aug 2025 · 6 months · monthly snapshot~Aug 2025 – ~Feb 2026 · 6 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

18 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting EARLY_PHASE1

  2. Aug 2025 — Feb 2026 [monthly]

    Active Not Recruiting EARLY_PHASE1

  3. Feb 2025 — Aug 2025 [monthly]

    Active Not Recruiting EARLY_PHASE1

  4. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting EARLY_PHASE1

▶ Show 13 earlier versions

  1. Dec 2023 — Jul 2024 [monthly]

    Recruiting EARLY_PHASE1

  2. Jun 2023 — Dec 2023 [monthly]

    Recruiting EARLY_PHASE1

  3. Jan 2023 — Jun 2023 [monthly]

    Recruiting EARLY_PHASE1

  4. Jul 2022 — Jan 2023 [monthly]

    Recruiting EARLY_PHASE1

  5. Dec 2021 — Jul 2022 [monthly]

    Recruiting EARLY_PHASE1

  6. Sep 2021 — Dec 2021 [monthly]

    Recruiting EARLY_PHASE1

  7. Mar 2021 — Sep 2021 [monthly]

    Recruiting EARLY_PHASE1

  8. Jan 2021 — Mar 2021 [monthly]

    Recruiting EARLY_PHASE1

  9. Jun 2020 — Jan 2021 [monthly]

    Recruiting EARLY_PHASE1

  10. Mar 2020 — Jun 2020 [monthly]

    Recruiting EARLY_PHASE1

  11. Sep 2019 — Mar 2020 [monthly]

    Recruiting EARLY_PHASE1

    Status: Not Yet Recruiting → Recruiting

  12. Jul 2019 — Sep 2019 [monthly]

    Not Yet Recruiting EARLY_PHASE1

  13. Jun 2019 — Jul 2019 [monthly]

    Not Yet Recruiting EARLY_PHASE1

    First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BTG International Inc.
  • OHSU Knight Cancer Institute
  • Oregon Health and Science University
Data source: OHSU Knight Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations